Borung’s 'Kanarb' is reaching to the top in 'single ingredient' section

(Yakup Shinmoon)

While there is an intense competition in ARB hypertension treatment market, domestic new drug 'Kanarb' from Boryung is reaching to the top in 'single ingredient' section.

According to the data from UB Care, in ARB single ingredient market (local hospitals and general hospitals combined), Kanarb made sales record of 2.41 billion won in December last year, and there was a...